Ajouter à une liste

Instrument Inactif

Communiqués BROE CAPI

Actions

BCAC

US11374E1047

Communiqués

18/08/22	BROE CAPI27 : INDEX TO UNAUDITED CONDENSED FINANCIAL STATEMENTS - Form 8-K/A	PU
04/08/22	BROE CAPI27 : UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION - Form 8-K	PU
01/08/22	Brookline Capital Acquisition : Apexigen Completes Business Combination to Become a Publicly Listed Immuno-oncology Company - Form 8-K	PU
28/07/22	BROOKLINE CAPITAL ACQUISITION : AND APEXIGEN, INC. ANNOUNCE STOCKHOLDER APPROVAL OF BUSINESS COMBINATION - Form 8-K	PU
18/07/22	Brookline Capital Acquisition : Apexigen and Brookline Capital Acquisition Corp. Announce Effectiveness of Registration Statement and Annual Stockholder Meeting to Approve the Proposed Business Combination - Form 8-K	PU
30/06/22	Brookline Capital Acquisition : Confirms Receipt of Sponsor Funds to Extend Period of Time to Consummate Business Combination and for Additional Working Capital - Form 8-K	PU
23/05/22	Brookline Capital Acquisition : Quarterly Report (Form 10-Q)	PU
27/04/22	Brookline Capital Acquisition : Announces Stockholder Approval of Extension Amendment to Complete its Business Combination with Apexigen, Inc - Form 8-K	PU
18/03/22	Brookline Capital Acquisition : VIAVID communications simplified. Apexigen and Brookline Capital Acquisition Corp. Joint Conference Call - Form 8-K	PU
18/03/22	Brookline Capital Acquisition : Apexigen and Brookline Capital Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Immuno-oncology Company - Form 8-K	PU
15/12/21	Brookline Capital Acquisition : Delisting/Failure to Satisfy Listing Rule/Transfer of Listing - Form 8-K	PU
24/11/21	Brookline Capital Acquisition : Amendment to Current Report (Form 8-K/A)	PU
07/06/21	Brookline Capital Acquisition : Quarterly Report (SEC Filing - 10-Q)	PU
04/06/21	Brookline Capital Acquisition : Receives Noncompliance Notice Regarding Late Form 10-Q Filing From Nasdaq (Form 8-K)	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Articles Zonebourse Analyses Zonebourse

Filtres

Espace mes listes

Palmarès

Suite du Palmarès

Palmarès

Suite du Palmarès

Devises / Forex

Matières Premières

Cryptomonnaies

Taux d'Intérêts

- 40% : Les Meilleurs Outils Réservés aux Abonnés pour Identifier les Meilleurs Investissements de Demain !

PROFITEZ-EN MAINTENANT